Your Shopping Cart Is Empty
| ✷ Report Code: A00002 | Feb 2022 | Pages: 211 | ||
| Tables: 107 | Charts: 61 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Protein Therapeutics Market
Request Now !The global protein therapeutics market size was valued at $283.64 Billion in 2020, and is estimated to reach $566.66 Billion by 2030, growing at a CAGR of 7.1% from 2021 to 2030. Therapeutic proteins are the medicines that are genetically engineered versions of naturally occurring human proteins. They can be used to replace a protein that is abnormal or deficient in a specific disease. They can also supplement supply of a beneficial protein, which can help mitigate effects of disease or chemotherapy. Genetically engineered proteins can be designed to closely resemble natural proteins they replace or they can be enhanced by addition of sugars or other molecules that extend the protein's activity duration.
The global protein therapeutics market in 2020 is anticipated to have a positive impact during the COVID-19 pandemic. The diagnosis and treatment of COVID-19 and other chronic diseases surged during the pandemic and thus demand for protein based therapeutic drugs was increased.
Therapeutic protein drugs are a type of medicine that are used to treat a variety of diseases such as cancer, metabolic, immunological, hematological, hormonal, genetic, infectious diseases, and others. These drugs have the potential to significantly improve human health. In principle, protein therapy is similar to gene therapy; which involves protein delivery in specific amounts to the body to facilitate precise functioning of different glands and other organs in the body
Growth of the protein therapeutics market is majorly driven by rise in prevalence of chronic diseases and development of plasma-derived therapies. Increase in prevalence of various diseases such as cancer, metabolic disorders, genetic disorders, and immunological diseases are expected to propel demand for protein therapeutics. In addition, according to the World Health Organization (WHO), cancer is a leading cause of death worldwide, and cancer cases are expected to increase significantly in the future. Thus, rise in prevalence of cancer is anticipated to drive the protein therapeutics market.
In addition, rise in proteomics research has further led to rise in the market growth. Protein microarray allows classification of proteins in a parallel and high-throughput way. The possibility of performing numerous assays in one small plate saves time of researchers and curbs the experiment cost. Growth in proteomic research is expected to lead to an increase in emergence of new protein drugs, which can further be used for treatment of various diseases.
However, high production costs required for developing as well as manufacturing protein-based therapeutics is expected to restrain growth of the market. Conversely, considerable rise in healthcare expenditure globally has led to the protein therapeutics market growth. Emerging economies of Asia-Pacific and LAMEA possess high potential for protein therapeutics. Growth in awareness regarding chronic diseases and use of proteins for treatment of these diseases has resulted in regulatory authorities in this region to take key decisions to improve legislations of protein therapeutics. Increase in geriatric population, growth in number of chronic diseases, and high requirement for protein therapeutics are expected to drive demand for these products over the next few years. In addition, emerging nations need to focus on cost-effectiveness and scalability to cater to the needs of the rising patient pool.
In addition, the COVID-19 outbreak is anticipated to have a positive impact on the protein therapeutics market. A huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. Non-essential procedures took a potential backlog, owing to rapid rise in COVID-19 cases. The lockdown led to disruption of manufacturing and transportation of healthcare essentials. However, diagnosis and treatment of COVID-19 and other diseases increased significantly during the pandemic, thus demand for protein based therapeutic drugs was increased.
The protein therapeutics market is segmented into product, application, and region. On the basis of product, it is classified into monoclonal antibodies, insulin, fusion protein, erythropoietin, interferon, human growth hormone, and follicle-stimulating hormone. On the basis of application, it is classified into metabolic disorders, immunologic disorders, hematological disorders, cancer, hormonal disorders, genetic disorders, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Segment Review
On the basis of product, the monoclonal antibodies segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to its wide range of availability, importance and applicability of these products in the treatment of different chronic disorders.
By application, the metabolic disorders segment dominated the market in 2020, and is expected to remain dominant during the forecast period, owing to requirement for quality drugs and versatile therapies for disease treatment, especially diabetes, which is expected to boost the growth of this segment.
North America exhibited the global protein therapeutics market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in prevalence of chronic diseases, adoption of technologically advanced treatments, presence of key players, and rise in healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to increase in R&D activities, increase in disposable incomes, and improvement in patient awareness toward protein therapeutics. Moreover, India and China are expected to grow at high CAGR in the Asia-Pacific protein therapeutics market.
Key Benefits for Stakeholders
Protein Therapeutics Market Report Highlights
| Aspects | Details |
|---|---|
| By PRODUCT |
|
| By APPLICATION |
|
| By Region |
|
| Key Market Players | Amgen Inc., Abbott Laboratories, Johnson and Johnson (Janssen Pharmaceuticals), Sanofi, Merck and Co., Inc., Baxter International Inc., Eli Lilly And Company, Pfizer Inc., Novo Nordisk AS, F. Hoffmann La Roche Ltd |
CHAPTER 1:INTRODUCTION
1.1.Report Description
1.2.Key Market Segments
1.3.Key Benefits
1.4.Research Methodology
1.4.1.Primary Research
1.4.2.Secondary Research
1.4.3.Analyst Tools and Models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.CXO Perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market Definition and Scope
3.2.Key Findings
3.2.1.Top Investment Pockets
3.2.2.Top Winning Strategies
3.3.Porter's Five Forces Analysis
3.3.1.Bargaining Power of Suppliers
3.3.2.Threat of New Entrants
3.3.3.Threat of Substitutes
3.3.4.Competitive Rivalry
3.3.5.Bargaining Power among Buyers
3.4.Market Share Analysis/Top Player Positioning
3.4.1.Market Share Analysis/Top Player Positioning 2020
3.5.Market Dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis
CHAPTER 4:PROTEIN THERAPEUTICS MARKET, BY PRODUCT
4.1.Market Overview
4.1.1Market Size and Forecast, By Product
4.2.Monoclonal Antibodies
4.2.1.Key Market Trends, Growth Factors and Opportunities
4.2.2.Market Size and Forecast, By Region
4.2.3.Market Share Analysis, By Country
4.3.Insulin
4.3.1.Key Market Trends, Growth Factors and Opportunities
4.3.2.Market Size and Forecast, By Region
4.3.3.Market Share Analysis, By Country
4.4.Fusion Protein
4.4.1.Key Market Trends, Growth Factors and Opportunities
4.4.2.Market Size and Forecast, By Region
4.4.3.Market Share Analysis, By Country
4.5.Erythropoietin
4.5.1.Key Market Trends, Growth Factors and Opportunities
4.5.2.Market Size and Forecast, By Region
4.5.3.Market Share Analysis, By Country
4.6.Interferon
4.6.1.Key Market Trends, Growth Factors and Opportunities
4.6.2.Market Size and Forecast, By Region
4.6.3.Market Share Analysis, By Country
4.7.Human Growth Hormone
4.7.1.Key Market Trends, Growth Factors and Opportunities
4.7.2.Market Size and Forecast, By Region
4.7.3.Market Share Analysis, By Country
4.8.Follicle Stimulating Hormone
4.8.1.Key Market Trends, Growth Factors and Opportunities
4.8.2.Market Size and Forecast, By Region
4.8.3.Market Share Analysis, By Country
CHAPTER 5:PROTEIN THERAPEUTICS MARKET, BY APPLICATION
5.1.Market Overview
5.1.1Market Size and Forecast, By Application
5.2.Metabolic Disorders
5.2.1.Market Size and Forecast, By Region
5.2.2.Market Share Analysis, By Country
5.3.Immunologic Disorders
5.3.1.Market Size and Forecast, By Region
5.3.2.Market Share Analysis, By Country
5.4.Hematological Disorders
5.4.1.Market Size and Forecast, By Region
5.4.2.Market Share Analysis, By Country
5.5.Cancer
5.5.1.Market Size and Forecast, By Region
5.5.2.Market Share Analysis, By Country
5.6.Hormonal Disorders
5.6.1.Market Size and Forecast, By Region
5.6.2.Market Share Analysis, By Country
5.7.Genetic Disorders
5.7.1.Market Size and Forecast, By Region
5.7.2.Market Share Analysis, By Country
5.8.Others
5.8.1.Market Size and Forecast, By Region
5.8.2.Market Share Analysis, By Country
CHAPTER 6:PROTEIN THERAPEUTICS MARKET, BY REGION
6.1.Market Overview
6.1.1Market Size and Forecast, By Region
6.2.North America
6.2.1.Key Market Trends and Opportunities
6.2.2.Market Size and Forecast, By Product
6.2.3.Market Size and Forecast, By Application
6.2.4.Market Size and Forecast, By Country
6.2.5.United States Protein Therapeutics Market
6.2.5.1.Market Size and Forecast, By Product
6.2.5.2.Market Size and Forecast, By Application
6.2.6.Canada Protein Therapeutics Market
6.2.6.1.Market Size and Forecast, By Product
6.2.6.2.Market Size and Forecast, By Application
6.2.7.Mexico Protein Therapeutics Market
6.2.7.1.Market Size and Forecast, By Product
6.2.7.2.Market Size and Forecast, By Application
6.3.Europe
6.3.1.Key Market Trends and Opportunities
6.3.2.Market Size and Forecast, By Product
6.3.3.Market Size and Forecast, By Application
6.3.4.Market Size and Forecast, By Country
6.3.5.France Protein Therapeutics Market
6.3.5.1.Market Size and Forecast, By Product
6.3.5.2.Market Size and Forecast, By Application
6.3.6.Germany Protein Therapeutics Market
6.3.6.1.Market Size and Forecast, By Product
6.3.6.2.Market Size and Forecast, By Application
6.3.7.Italy Protein Therapeutics Market
6.3.7.1.Market Size and Forecast, By Product
6.3.7.2.Market Size and Forecast, By Application
6.3.8.Spain Protein Therapeutics Market
6.3.8.1.Market Size and Forecast, By Product
6.3.8.2.Market Size and Forecast, By Application
6.3.9.U.K Protein Therapeutics Market
6.3.9.1.Market Size and Forecast, By Product
6.3.9.2.Market Size and Forecast, By Application
6.3.10.Rest of Europe Protein Therapeutics Market
6.3.10.1.Market Size and Forecast, By Product
6.3.10.2.Market Size and Forecast, By Application
6.4.Asia-Pacific
6.4.1.Key Market Trends and Opportunities
6.4.2.Market Size and Forecast, By Product
6.4.3.Market Size and Forecast, By Application
6.4.4.Market Size and Forecast, By Country
6.4.5.China Protein Therapeutics Market
6.4.5.1.Market Size and Forecast, By Product
6.4.5.2.Market Size and Forecast, By Application
6.4.6.Japan Protein Therapeutics Market
6.4.6.1.Market Size and Forecast, By Product
6.4.6.2.Market Size and Forecast, By Application
6.4.7.India Protein Therapeutics Market
6.4.7.1.Market Size and Forecast, By Product
6.4.7.2.Market Size and Forecast, By Application
6.4.8.South Korea Protein Therapeutics Market
6.4.8.1.Market Size and Forecast, By Product
6.4.8.2.Market Size and Forecast, By Application
6.4.9.Australia Protein Therapeutics Market
6.4.9.1.Market Size and Forecast, By Product
6.4.9.2.Market Size and Forecast, By Application
6.4.10.Rest of Asia Pacific Protein Therapeutics Market
6.4.10.1.Market Size and Forecast, By Product
6.4.10.2.Market Size and Forecast, By Application
6.5.LAMEA
6.5.1.Key Market Trends and Opportunities
6.5.2.Market Size and Forecast, By Product
6.5.3.Market Size and Forecast, By Application
6.5.4.Market Size and Forecast, By Country
6.5.5.Brazil Protein Therapeutics Market
6.5.5.1.Market Size and Forecast, By Product
6.5.5.2.Market Size and Forecast, By Application
6.5.6.South Africa, Protein Therapeutics Market
6.5.6.1.Market Size and Forecast, By Product
6.5.6.2.Market Size and Forecast, By Application
6.5.7.Saudi Arabia Protein Therapeutics Market
6.5.7.1.Market Size and Forecast, By Product
6.5.7.2.Market Size and Forecast, By Application
6.5.8.Rest of LAMEA Protein Therapeutics Market
6.5.8.1.Market Size and Forecast, By Product
6.5.8.2.Market Size and Forecast, By Application
CHAPTER 7:COMPANY PROFILES
7.1.Abbott Laboratories
7.1.1.Company Overview
7.1.2.Key Executives
7.1.3.Company snapshot
7.1.4.Operating business segments
7.1.5.Product portfolio
7.1.6.Business Performance
7.1.7.Key Strategic Moves and Developments
7.2.Amgen Inc.
7.2.1.Company Overview
7.2.2.Key Executives
7.2.3.Company snapshot
7.2.4.Operating business segments
7.2.5.Product portfolio
7.2.6.Business Performance
7.2.7.Key Strategic Moves and Developments
7.3.Baxter International Inc.
7.3.1.Company Overview
7.3.2.Key Executives
7.3.3.Company snapshot
7.3.4.Operating business segments
7.3.5.Product portfolio
7.3.6.Business Performance
7.3.7.Key Strategic Moves and Developments
7.4.Eli Lilly And Company
7.4.1.Company Overview
7.4.2.Key Executives
7.4.3.Company snapshot
7.4.4.Operating business segments
7.4.5.Product portfolio
7.4.6.Business Performance
7.4.7.Key Strategic Moves and Developments
7.5.F. Hoffmann La Roche Ltd
7.5.1.Company Overview
7.5.2.Key Executives
7.5.3.Company snapshot
7.5.4.Operating business segments
7.5.5.Product portfolio
7.5.6.Business Performance
7.5.7.Key Strategic Moves and Developments
7.6.Johnson and Johnson (Janssen Pharmaceuticals)
7.6.1.Company Overview
7.6.2.Key Executives
7.6.3.Company snapshot
7.6.4.Operating business segments
7.6.5.Product portfolio
7.6.6.Business Performance
7.6.7.Key Strategic Moves and Developments
7.7.Merck and Co., Inc.
7.7.1.Company Overview
7.7.2.Key Executives
7.7.3.Company snapshot
7.7.4.Operating business segments
7.7.5.Product portfolio
7.7.6.Business Performance
7.7.7.Key Strategic Moves and Developments
7.8.Novo Nordisk AS
7.8.1.Company Overview
7.8.2.Key Executives
7.8.3.Company snapshot
7.8.4.Operating business segments
7.8.5.Product portfolio
7.8.6.Business Performance
7.8.7.Key Strategic Moves and Developments
7.9.Pfizer Inc.
7.9.1.Company Overview
7.9.2.Key Executives
7.9.3.Company snapshot
7.9.4.Operating business segments
7.9.5.Product portfolio
7.9.6.Business Performance
7.9.7.Key Strategic Moves and Developments
7.10.Sanofi
7.10.1.Company Overview
7.10.2.Key Executives
7.10.3.Company snapshot
7.10.4.Operating business segments
7.10.5.Product portfolio
7.10.6.Business Performance
7.10.7.Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1.GLOBAL PROTEIN THERAPEUTICS MARKET, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 2.GLOBAL PROTEIN THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2020-2030 ($MILLION)
TABLE 3.GLOBAL PROTEIN THERAPEUTICS MARKET FOR INSULIN, BY REGION, 2020-2030 ($MILLION)
TABLE 4.GLOBAL PROTEIN THERAPEUTICS MARKET FOR FUSION PROTEIN, BY REGION, 2020-2030 ($MILLION)
TABLE 5.GLOBAL PROTEIN THERAPEUTICS MARKET FOR ERYTHROPOIETIN, BY REGION, 2020-2030 ($MILLION)
TABLE 6.GLOBAL PROTEIN THERAPEUTICS MARKET FOR INTERFERON, BY REGION, 2020-2030 ($MILLION)
TABLE 7.GLOBAL PROTEIN THERAPEUTICS MARKET FOR HUMAN GROWTH HORMONE, BY REGION, 2020-2030 ($MILLION)
TABLE 8.GLOBAL PROTEIN THERAPEUTICS MARKET FOR FOLLICLE STIMULATING HORMONE, BY REGION, 2020-2030 ($MILLION)
TABLE 9.GLOBAL PROTEIN THERAPEUTICS MARKET, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 10.GLOBAL PROTEIN THERAPEUTICS MARKET FOR METABOLIC DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 11.GLOBAL PROTEIN THERAPEUTICS MARKET FOR IMMUNOLOGIC DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 12.GLOBAL PROTEIN THERAPEUTICS MARKET FOR HEMATOLOGICAL DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 13.GLOBAL PROTEIN THERAPEUTICS MARKET FOR CANCER, BY REGION, 2020-2030 ($MILLION)
TABLE 14.GLOBAL PROTEIN THERAPEUTICS MARKET FOR HORMONAL DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 15.GLOBAL PROTEIN THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY REGION, 2020-2030 ($MILLION)
TABLE 16.GLOBAL PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
TABLE 17.GLOBAL PROTEIN THERAPEUTICS MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 20.UNITED STATES PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 21.UNITED STATES PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 22.CANADA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 23.CANADA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 24.MEXICO PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 25.MEXICO PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 26.EUROPE PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 27.EUROPE PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 28.FRANCE PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 29.FRANCE PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 30.GERMANY PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 31.GERMANY PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 32.ITALY PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 33.ITALY PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 34.SPAIN PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 35.SPAIN PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 36.UNITED KINGDOM PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 37.UNITED KINGDOM PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 38.REST OF EUROPE PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 39.REST OF EUROPE PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 40.ASIA-PACIFIC PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 41.ASIA-PACIFIC PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 42.CHINA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 43.CHINA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 44.JAPAN PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 45.JAPAN PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 46.INDIA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 47.INDIA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 48.SOUTH KOREA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 49.SOUTH KOREA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 50.AUSTRALIA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 51.AUSTRALIA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 52.REST OF ASIA PACIFIC PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 53.REST OF ASIA PACIFIC PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 54.LAMEA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 55.LAMEA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 56.BRAZIL PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 57.BRAZIL PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 58.SOUTH AFRICA, PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 59.SOUTH AFRICA, PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 60.SAUDI ARABIA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 61.SAUDI ARABIA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 62.REST OF LAMEA PROTEIN THERAPEUTICS, BY PRODUCT, 2020-2030 ($MILLION)
TABLE 63.REST OF LAMEA PROTEIN THERAPEUTICS, BY APPLICATION, 2020-2030 ($MILLION)
TABLE 64.ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 65.ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 66.ABBOTT LABORATORIES: OPERATING SEGMENTS
TABLE 67.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 68.AMGEN INC.: KEY EXECUTIVES
TABLE 69.AMGEN INC.: COMPANY SNAPSHOT
TABLE 70.AMGEN INC.: OPERATING SEGMENTS
TABLE 71.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 72.AMGEN INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 73.BAXTER INTERNATIONAL INC.: KEY EXECUTIVES
TABLE 74.BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT
TABLE 75.BAXTER INTERNATIONAL INC.: OPERATING SEGMENTS
TABLE 76.BAXTER INTERNATIONAL INC.: PRODUCT PORTFOLIO
TABLE 77.ELI LILLY AND COMPANY: KEY EXECUTIVES
TABLE 78.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
TABLE 79.ELI LILLY AND COMPANY: OPERATING SEGMENTS
TABLE 80.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
TABLE 81.ELI LILLY AND COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 82.F. HOFFMANN LA ROCHE LTD: KEY EXECUTIVES
TABLE 83.F. HOFFMANN LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 84.F. HOFFMANN LA ROCHE LTD: OPERATING SEGMENTS
TABLE 85.F. HOFFMANN LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 86.F. HOFFMANN LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 87.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): KEY EXECUTIVES
TABLE 88.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 89.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): OPERATING SEGMENTS
TABLE 90.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 91.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92.MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 93.MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 94.MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 95.MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 96.MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97.NOVO NORDISK AS: KEY EXECUTIVES
TABLE 98.NOVO NORDISK AS: COMPANY SNAPSHOT
TABLE 99.NOVO NORDISK AS: OPERATING SEGMENTS
TABLE 100.NOVO NORDISK AS: PRODUCT PORTFOLIO
TABLE 101.NOVO NORDISK AS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102.PFIZER INC.: KEY EXECUTIVES
TABLE 103.PFIZER INC.: COMPANY SNAPSHOT
TABLE 104.PFIZER INC.: OPERATING SEGMENTS
TABLE 105.PFIZER INC.: PRODUCT PORTFOLIO
TABLE 106.PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107.SANOFI: KEY EXECUTIVES
TABLE 108.SANOFI: COMPANY SNAPSHOT
TABLE 109.SANOFI: OPERATING SEGMENTS
TABLE 110.SANOFI: PRODUCT PORTFOLIO
TABLE 111.SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1.GLOBAL PROTEIN THERAPEUTICS MARKET SEGMENTATION
FIGURE 2.GLOBAL PROTEIN THERAPEUTICS MARKET
FIGURE 3.SEGMENTATION PROTEIN THERAPEUTICS MARKET
FIGURE 4.TOP INVESTMENT POCKET IN PROTEIN THERAPEUTICS MARKET
FIGURE 5.TOP WINNING STRATEGIES, 2019-2021*
FIGURE 6.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2019-2021(%)
FIGURE 7.TOP WINNING STRATEGIES, BY COMPANY, 2019-2021*
FIGURE 8.MODERATE BARGAINING POWER OF BUYERS
FIGURE 9.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF NEW ENTRANTS
FIGURE 11.LOW THREAT OF SUBSTITUTION
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.TOP PLAYER POSITIONING, 2020
FIGURE 14.MARKET SHARE ANALYSIS, 2020
FIGURE 15.RESTRAINTS AND DRIVERS: PROTEIN THERAPEUTICS MARKET
FIGURE 16.PROTEIN THERAPEUTICS MARKET SEGMENTATION, BY PRODUCT
FIGURE 17.PROTEIN THERAPEUTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.PROTEIN THERAPEUTICS MARKET FOR INSULIN, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 19.PROTEIN THERAPEUTICS MARKET FOR FUSION PROTEIN, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 20.PROTEIN THERAPEUTICS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 21.PROTEIN THERAPEUTICS MARKET FOR INTERFERON, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 22.PROTEIN THERAPEUTICS MARKET FOR HUMAN GROWTH HORMONE, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 23.PROTEIN THERAPEUTICS MARKET FOR FOLLICLE STIMULATING HORMONE, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 24.PROTEIN THERAPEUTICS MARKET SEGMENTATION, BY APPLICATION
FIGURE 25.PROTEIN THERAPEUTICS MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 26.PROTEIN THERAPEUTICS MARKET FOR IMMUNOLOGIC DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 27.PROTEIN THERAPEUTICS MARKET FOR HEMATOLOGICAL DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 28.PROTEIN THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 29.PROTEIN THERAPEUTICS MARKET FOR HORMONAL DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 30.PROTEIN THERAPEUTICS MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 31.PROTEIN THERAPEUTICS MARKET FOR OTHERS, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 32.ABBOTT LABORATORIES: NET SALES, 2018-2020 ($MILLION)
FIGURE 33.ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 34.ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.AMGEN INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 36.AMGEN INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.AMGEN INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.BAXTER INTERNATIONAL INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 39.BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.BAXTER INTERNATIONAL INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 41.ELI LILLY AND COMPANY: NET SALES, 2018-2020 ($MILLION)
FIGURE 42.ELI LILLY AND COMPANY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 43.ELI LILLY AND COMPANY: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 44.F. HOFFMANN LA ROCHE LTD: NET SALES, 2018-2020 ($MILLION)
FIGURE 45.F. HOFFMANN LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 46.F. HOFFMANN LA ROCHE LTD: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 47.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): NET SALES, 2018-2020 ($MILLION)
FIGURE 48.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 49.JOHNSON AND JOHNSON (JANSSEN PHARMACEUTICALS): REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 50.MERCK AND CO., INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 51.MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 52.MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 53.NOVO NORDISK AS: NET SALES, 2018-2020 ($MILLION)
FIGURE 54.NOVO NORDISK AS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 55.NOVO NORDISK AS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 56.PFIZER INC.: NET SALES, 2018-2020 ($MILLION)
FIGURE 57.PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 58.PFIZER INC.: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 59.SANOFI: NET SALES, 2018-2020 ($MILLION)
FIGURE 60.SANOFI: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 61.SANOFI: REVENUE SHARE, BY REGION, 2020 (%)
This section provides opinions of top-level CXOs in the biotechnological & pharmaceutical industry. According to CXOs, protein therapeutics have positively impacted diverse fields of disease treatment and prognosis. Diseases that were otherwise debilitating and life threatening can be managed through administration of these drugs. These drugs have also contributed significantly in diagnosis and prevention of oncologic, metabolic, immunologic, genetic, and other chronic diseases.
CXOs further state that protein therapeutics are expected to witness high adoption rate with increase in distinct indications and interventions, such as lymphomas, diabetes, hepatitis, and leukemia. The global protein therapeutics market has witnessed significant momentum in the healthcare industry and pharmaceutical sector, owing to favorable government policies, conducive regulations abiding protein therapeutics, and growth in proteomics research. However, high development & manufacturing cost, high treatment costs per patient, stringent government regulations, and complex reimbursement scenario restrict the market growth.
North America is expected to witness highest growth, in terms of revenue during the forecast period, owing to rise in chronic diseases, adoption of technologically advanced treatments in this region, presence of key players, and advancements in healthcare investments. However, Asia-Pacific, is expected to grow significantly, owing to its high population base, surge of diseases, increase in disposable incomes, and improvement in patient awareness toward protein therapeutics.
A. The total market value of protein therapeutics market is $283.64 billion in 2020.
A. The forecast period for protein therapeutics market is 2021 to 2030
A. The market value of protein therapeutics market in 2021 is $304.52 billion.
A. The base year is 2020 in protein therapeutics market
A. Top companies such as Abbott Laboratories, Amgen Inc., Baxter International Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Pharmaceuticals), Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., and Sanofi, held a high market position in 2020.
A. Monoclonal antibodies segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to availability of wide range of protein therapeutics based on monoclonal antibodies and applicability of these products in the treatment of different chronic disorders is expected to drive the segment
A. Increase in prevalence of chronic diseases, rising patient pool and various technological advancements in protein therapeutics is anticipated to drive the market in the forecast period.
A. North America is projected to account for a major share of the global protein therapeutics market during the forecast period. U.S. dominated the North America protein therapeutics market owing to increased chronic chrnic diseases, adoption of technologically advanced therapies and health awareness across the country.
Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report